SCHEMBL6534880

SCHEMBL6534880

[CH2]c1ccc(OCC)cc1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.52
NQO1 P15559 1/20 0.50
ALDH1A1 P00352 3/20 0.49
MAPT P10636 3/20 0.49
HSD17B10 Q99714 2/20 0.49
HPGD P15428 2/20 0.44
SLC5A1 P13866 2/20 0.43
SLC5A2 P31639 2/20 0.43
CHEK1 O14757 1/20 0.43
DAPK3 O43293 1/20 0.43
PRKD3 O94806 1/20 0.43
PIM1 P11309 1/20 0.43
MAPK8 P45983 1/20 0.43
CSNK1A1 P48729 1/20 0.43
CDK8 P49336 1/20 0.43
CLK2 P49760 1/20 0.43
CDK9 P50750 1/20 0.43
CDK5 Q00535 1/20 0.43
DYRK1A Q13627 1/20 0.43
LRRK2 Q5S007 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9782924 0.85 LTA4H (0.55) LTA4HALDH1A1MAPTMEN1KMT2A
SCHEMBL1051397 0.81 LTA4H (0.57) LTA4HNQO1ALDH1A1MAPTHSD17B10
SCHEMBL339500 0.81 LTA4H (0.57) LTA4HNQO1ALDH1A1MAPTHSD17B10
Alcohol SCHEMBL27353807 0.78 LTA4H (0.53) LTA4HNQO1ALDH1A1MAPTHSD17B10
SCHEMBL6799758 0.78 NQO1 (0.52) LTA4HNQO1ALDH1A1MAPTHSD17B10
SCHEMBL4229019 0.78 LTA4H (0.53) LTA4HNQO1ALDH1A1MAPTHSD17B10
SCHEMBL4960422 0.78 LTA4H (0.53) LTA4HNQO1ALDH1A1MAPTHSD17B10
SCHEMBL28929724 0.78 NQO1 (0.52) LTA4HNQO1ALDH1A1MAPTHSD17B10
SCHEMBL130818 0.77 TRIM24 (0.57) LTA4HALDH1A1MAPTHPGDMEN1
SCHEMBL7682786 0.76 NQO1 (0.50) LTA4HNQO1ALDH1A1MAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171437-A1 PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO VERA THERAPEUTICS INC (US) 2021-06-10 US disclosed
EP-1115739-A4 AUXILIARY FOR AMIDE BOND FORMATION UNIV QUEENSLAND (AU) 2004-10-27 EP disclosed
EP-1115739-A1 AUXILIARY FOR AMIDE BOND FORMATION THE UNIVERSITY OF QUEENSLAND (AU) 2001-07-18 EP disclosed
WO-2000018789-A1 AUXILIARY FOR AMIDE BOND FORMATION THE UNIVERSITY OF QUEENSLAND (AU) 2000-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171437-A1 PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO TARBP1, TIA1, SSB LTA4H 3555/4885NQO1 4713/4885ALDH1A1 4569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.